Posts

Novo Nordisk Bets on HERMES and ARTEMIS to Salvage Ziltivekimab CKD Program After ZEUS Failure

on

Pfizer'

on

Can Intellia's lonvo-z Turn CRISPR Promise into HAE Practice?

on

Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3

on

Abivax stock falls on cancer cases despite strong ulcerative colitis phase 3 data

on

Lilly's triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile

on

Can Revolution's miracle pancreatic cancer drug be topped? Immuneering, Actuate say yes – BioSpace, Stat News, and clinical trial updates, May 2026

on

Boehringer Ingelheim and Zealand Pharma's Survodutide Matches Wegovy in Weight Loss but Trails Zepbound in Phase 3 Trial

on

Roche Launches New Phase 3 Trial for Elevidys to Address EU Rejection in DMD

on

Vertex's Povetacicept Clears Phase 3 Milestone in IgA Nephropathy: Blockbuster Potential Ahead?

on

Aardvark Therapeutics Stock Plunges 54% Following Phase 3 Trial Pause

on

Ocular Therapeutix's Axpaxli Demonstrates Superiority Over Regeneron's Eylea in Phase 3 Trial for Wet AMD

on

Compass Pathways Stock Soars on Second Phase 3 Success for Psilocybin Depression Treatment

on

Neurocrine's VMAT2 Inhibitor Valbenazine Fails in Phase 3 Trial for Dyskinetic Cerebral Palsy

on

Moderna Lands CEPI as New Backer for Its Pandemic Flu (H5 Bird Flu) Program

on

Enliven Therapeutics Announces New CEO

on

Bayer Stock Rallies as Next-Gen Blood Thinner Achieves Phase 3 Success

on

Roche's Oral SERD Giredestrant Delays Early Breast Cancer Recurrence in Late-Stage Trial

on

FDA Extends Review Period for Rhythm Pharmaceuticals’ Imcivree (Setmelanotide) in Acquired Hypothalamic Obesity

on